datopotamab deruxtecan (Enhertu)

Indications

• non-small cell lung cancer (NSCLC):
  • advanced, non-squamous NSCLC who have received prior platinum-based chemotherapy
• breast cancer:
  • HER2-negative, hormone receptor-positive metastatic breast cancer with prior endocrine therapy & chemotherapy.

Dosage

• intravenous infusion every 3 weeks

Adverse effects

• nausea/vomiting, diarrhea
• fatigue
• pancytopenia
• mucositis

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• targets TROP2 (trophoblast cell-surface antigen 2), a protein found on the surface of cancer cells.
  • datopotamab is a monocloal Ab, deruxtecan is an antineoplastic agent
  • once attached datopotamab deruxtecan releases deruxtecan into the cancer cell

More general terms

• antineoplastic monoclonal antibody